Ultragenyx Pharmaceutical (RARE)
(Delayed Data from NSDQ)
$44.24 USD
+0.39 (0.89%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $44.23 -0.01 (-0.02%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth F Momentum F VGM
Income Statements
Fiscal Year end for Ultragenyx Pharmaceutical Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 434 | 363 | 351 | 271 | 104 |
Cost Of Goods | 45 | 28 | 16 | 6 | 9 |
Gross Profit | 389 | 335 | 335 | 265 | 95 |
Selling & Adminstrative & Depr. & Amort Expenses | 958 | 984 | 717 | 595 | 519 |
Income After Depreciation & Amortization | -569 | -649 | -382 | -330 | -424 |
Non-Operating Income | 27 | -10 | -42 | 178 | 26 |
Interest Expense | 66 | 43 | 29 | 33 | 1 |
Pretax Income | -608 | -702 | -453 | -185 | -399 |
Income Taxes | -2 | 6 | 1 | 1 | 3 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -607 | -707 | -454 | -187 | -403 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -607 | -707 | -454 | -187 | -403 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -556 | -628 | -362 | -317 | -422 |
Depreciation & Amortization (Cash Flow) | 13 | 21 | 20 | 13 | 2 |
Income After Depreciation & Amortization | -569 | -649 | -382 | -330 | -424 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 73.54 | 69.91 | 67.80 | 60.85 | 56.58 |
Diluted EPS Before Non-Recurring Items | -8.25 | -9.05 | -6.34 | -5.28 | -7.36 |
Diluted Net EPS (GAAP) | -8.25 | -10.12 | -6.70 | -3.07 | -7.12 |
Fiscal Year end for Ultragenyx Pharmaceutical Inc falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 127.39 | 98.05 | 108.31 | 100.50 |
Cost Of Goods | NA | 12.05 | 10.99 | 9.91 | 12.26 |
Gross Profit | NA | 115.34 | 87.07 | 98.40 | 88.24 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 237.39 | 232.17 | 246.35 | 242.35 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -122.05 | -145.10 | -147.95 | -154.11 |
Non-Operating Income | NA | 12.49 | 3.76 | 4.24 | 6.26 |
Interest Expense | NA | 17.33 | 17.67 | 15.38 | 15.64 |
Pretax Income | NA | -126.89 | -159.00 | -159.10 | -163.48 |
Income Taxes | NA | -3.70 | 0.65 | 0.73 | 0.50 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -123.19 | -159.65 | -159.83 | -163.97 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -123.19 | -159.65 | -159.83 | -163.97 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | 81.12 | 71.67 | 70.90 | 70.37 |
Diluted EPS Before Non-Recurring Items | NA | -1.52 | -2.23 | -2.25 | -2.33 |
Diluted Net EPS (GAAP) | NA | -1.44 | -2.23 | -2.25 | -2.33 |